2020
DOI: 10.31031/tnn.2020.03.000572
|View full text |Cite
|
Sign up to set email alerts
|

Recent Advances in the Treatment of Opioid Use Disorders

Abstract: For pharmacotherapy of opioid use disorders treatment with oral methadone or sublingual buprenorphine are established first-line treatments. Recently three novel long-acting buprenorphine depot or implant formulations have been studieD and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly depot formulation RBP-6000 [Sublocade™] and the six-month buprenorphine implant [Probuphine™]. The pharmacology and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 53 publications
0
1
0
Order By: Relevance
“…Local anaesthetics and non-steroidal anti-inflammatory drugs (NSAIDs) provide pain relief, enhance tissue recovery and reduce inflammation (Hollmann et al 2000 ), which is especially important during the inflammatory phase of wound healing, which may last for up to four days post-surgery (Artlett 2013 ). There have been several studies on longer-acting analgesic agents, such as meloxicam (Bourne et al 2010 ; Bauer et al 2014 ), bupivacaine (Bourne et al 2010 ; Lascelles & Kirkby Shaw 2016 ), tramadol (Bourne et al 2010 ; Fleming & Burn 2014 ) and buprenorphine (Bourne et al 2010 ; Soyka 2020 ), which show promising results in various bear species in captivity as well as long-tailed macaques ( Macaca fascicularis ), cats ( Felis catus ), dogs and humans. It is worth mentioning however that the pharmacokinetics, therapeutic windows and possible side-effects of these drugs are not tested in bears but ongoing clinical use on bears in captivity supports clinical efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…Local anaesthetics and non-steroidal anti-inflammatory drugs (NSAIDs) provide pain relief, enhance tissue recovery and reduce inflammation (Hollmann et al 2000 ), which is especially important during the inflammatory phase of wound healing, which may last for up to four days post-surgery (Artlett 2013 ). There have been several studies on longer-acting analgesic agents, such as meloxicam (Bourne et al 2010 ; Bauer et al 2014 ), bupivacaine (Bourne et al 2010 ; Lascelles & Kirkby Shaw 2016 ), tramadol (Bourne et al 2010 ; Fleming & Burn 2014 ) and buprenorphine (Bourne et al 2010 ; Soyka 2020 ), which show promising results in various bear species in captivity as well as long-tailed macaques ( Macaca fascicularis ), cats ( Felis catus ), dogs and humans. It is worth mentioning however that the pharmacokinetics, therapeutic windows and possible side-effects of these drugs are not tested in bears but ongoing clinical use on bears in captivity supports clinical efficacy.…”
Section: Discussionmentioning
confidence: 99%